Cargando…
Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation
Magnesium isoglycyrrhizinate (MGL) is a new stereoisomer of glycyrrhizic acid, which is clinically used as a hepatoprotective medicine with more potent effects and less side effects than glycyrrhizic acid. This study was designed to evaluate the protective effects and possible mechanism of MGL again...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734720/ https://www.ncbi.nlm.nih.gov/pubmed/26869766 http://dx.doi.org/10.2147/DDDT.S92440 |
_version_ | 1782412960173391872 |
---|---|
author | Yang, Qi Wang, Jianwei Liu, Ran Wang, Zhiqiang Li, Yufeng Zhang, Yifan Hao, Xiaohua Huang, Yubo Xie, Wen Wei, Hongshan |
author_facet | Yang, Qi Wang, Jianwei Liu, Ran Wang, Zhiqiang Li, Yufeng Zhang, Yifan Hao, Xiaohua Huang, Yubo Xie, Wen Wei, Hongshan |
author_sort | Yang, Qi |
collection | PubMed |
description | Magnesium isoglycyrrhizinate (MGL) is a new stereoisomer of glycyrrhizic acid, which is clinically used as a hepatoprotective medicine with more potent effects and less side effects than glycyrrhizic acid. This study was designed to evaluate the protective effects and possible mechanism of MGL against concanavalin A (Con A)-induced autoimmune hepatitis. Hepatitis was induced by Con A in C57/6J mice with or without MGL administration; injury score and serum ALT were evaluated. The CD4(+) T-cells were isolated from splenocytes and challenged with Con A after coculturing with MGL. The injury score was significantly improved in MGL-treated mice after Con A challenging for 12 and 24 hours compared with those merely challenged with Con A. Similar trends were observed in the serum levels of ALT and AST. The most interesting result was that MGL administration significantly decreased the frequency of CD4(+)CD25(−)CD69(+) T-cells rather than CD4(+)CD25(+)CD69(+) T-cells in peripheral blood mononuclear cells, after Con A challenging 12 and 24 hours. Moreover, the serum ALT levels were markedly correlated with the frequency of CD4(+)CD25(−)CD69(+) cells, but only weakly correlated with CD4(+)CD25(+)CD69(+) cells in peripheral blood mononuclear cells. More importantly, MGL (5 mg/mL) almost completely eliminated the proliferation of the CD25(−)CD69(+) subset in primary CD4(+) T-cells after Con A challenge. Compared with merely Con A-challenged mice, those with MGL administration significantly demonstrated decreased NALP3, NLRP6, and caspase-3 expression, in which the NALP3 and caspase-3 downregulated in a dose-dependent manner. Our results indicate that MGL may have potential as a therapeutic agent in autoimmune hepatitis by ameliorating liver injury. Its molecular mechanism may be involved in inhibiting CD4(+)CD25(−)CD69(+) subset proliferation and downregulating inflammasome expression in liver tissue. |
format | Online Article Text |
id | pubmed-4734720 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-47347202016-02-11 Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation Yang, Qi Wang, Jianwei Liu, Ran Wang, Zhiqiang Li, Yufeng Zhang, Yifan Hao, Xiaohua Huang, Yubo Xie, Wen Wei, Hongshan Drug Des Devel Ther Original Research Magnesium isoglycyrrhizinate (MGL) is a new stereoisomer of glycyrrhizic acid, which is clinically used as a hepatoprotective medicine with more potent effects and less side effects than glycyrrhizic acid. This study was designed to evaluate the protective effects and possible mechanism of MGL against concanavalin A (Con A)-induced autoimmune hepatitis. Hepatitis was induced by Con A in C57/6J mice with or without MGL administration; injury score and serum ALT were evaluated. The CD4(+) T-cells were isolated from splenocytes and challenged with Con A after coculturing with MGL. The injury score was significantly improved in MGL-treated mice after Con A challenging for 12 and 24 hours compared with those merely challenged with Con A. Similar trends were observed in the serum levels of ALT and AST. The most interesting result was that MGL administration significantly decreased the frequency of CD4(+)CD25(−)CD69(+) T-cells rather than CD4(+)CD25(+)CD69(+) T-cells in peripheral blood mononuclear cells, after Con A challenging 12 and 24 hours. Moreover, the serum ALT levels were markedly correlated with the frequency of CD4(+)CD25(−)CD69(+) cells, but only weakly correlated with CD4(+)CD25(+)CD69(+) cells in peripheral blood mononuclear cells. More importantly, MGL (5 mg/mL) almost completely eliminated the proliferation of the CD25(−)CD69(+) subset in primary CD4(+) T-cells after Con A challenge. Compared with merely Con A-challenged mice, those with MGL administration significantly demonstrated decreased NALP3, NLRP6, and caspase-3 expression, in which the NALP3 and caspase-3 downregulated in a dose-dependent manner. Our results indicate that MGL may have potential as a therapeutic agent in autoimmune hepatitis by ameliorating liver injury. Its molecular mechanism may be involved in inhibiting CD4(+)CD25(−)CD69(+) subset proliferation and downregulating inflammasome expression in liver tissue. Dove Medical Press 2016-01-25 /pmc/articles/PMC4734720/ /pubmed/26869766 http://dx.doi.org/10.2147/DDDT.S92440 Text en © 2016 Yang et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Yang, Qi Wang, Jianwei Liu, Ran Wang, Zhiqiang Li, Yufeng Zhang, Yifan Hao, Xiaohua Huang, Yubo Xie, Wen Wei, Hongshan Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title | Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title_full | Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title_fullStr | Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title_full_unstemmed | Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title_short | Amelioration of concanavalin A-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of CD4(+)CD25(−)CD69(+) subset proliferation |
title_sort | amelioration of concanavalin a-induced autoimmune hepatitis by magnesium isoglycyrrhizinate through inhibition of cd4(+)cd25(−)cd69(+) subset proliferation |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734720/ https://www.ncbi.nlm.nih.gov/pubmed/26869766 http://dx.doi.org/10.2147/DDDT.S92440 |
work_keys_str_mv | AT yangqi ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT wangjianwei ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT liuran ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT wangzhiqiang ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT liyufeng ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT zhangyifan ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT haoxiaohua ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT huangyubo ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT xiewen ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation AT weihongshan ameliorationofconcanavalinainducedautoimmunehepatitisbymagnesiumisoglycyrrhizinatethroughinhibitionofcd4cd25cd69subsetproliferation |